GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHVF) » Definitions » Capex-to-Revenue

Roche Holding AG (Roche Holding AG) Capex-to-Revenue : 0.09 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Roche Holding AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Roche Holding AG's Capital Expenditure for the six months ended in Dec. 2023 was $-3,093.20 Mil. Its Revenue for the six months ended in Dec. 2023 was $34,487.74 Mil.

Hence, Roche Holding AG's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.09.


Roche Holding AG Capex-to-Revenue Historical Data

The historical data trend for Roche Holding AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Capex-to-Revenue Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.12 0.07 0.07 0.08

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.06 0.08 0.06 0.09

Competitive Comparison of Roche Holding AG's Capex-to-Revenue

For the Drug Manufacturers - General subindustry, Roche Holding AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Capex-to-Revenue falls into.



Roche Holding AG Capex-to-Revenue Calculation

Roche Holding AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-5375.809) / 69890.148
=0.08

Roche Holding AG's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-3093.201) / 34487.743
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG  (OTCPK:RHHVF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Roche Holding AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus